Guo J, Jiang X, Tian Y, Yan S, Liu J, Xie J
Pharmaceuticals (Basel). 2025; 17(12.
PMID: 39770541
PMC: 11677886.
DOI: 10.3390/ph17121700.
Sollars V, Chapman A, Liang N, Myers S
J Breast Cancer Res. 2024; 4(1):5-10.
PMID: 39363892
PMC: 11448696.
DOI: 10.46439/breastcancer.4.021.
Strzempek W, Menaszek E, Papiez M, Gil B
Molecules. 2024; 29(16).
PMID: 39202897
PMC: 11357391.
DOI: 10.3390/molecules29163818.
Kulkarni A, Mohan V, Tang T, Post L, Chan Y, Manning M
EMBO Rep. 2024; 25(9):3944-3969.
PMID: 39103676
PMC: 11387499.
DOI: 10.1038/s44319-024-00217-3.
Kruschel R, Barbosa M, Almeida M, Xavier C, Vasconcelos M, McCarthy F
J Med Chem. 2024; 67(16):13909-13924.
PMID: 39093920
PMC: 11345829.
DOI: 10.1021/acs.jmedchem.4c00705.
scNovel: a scalable deep learning-based network for novel rare cell discovery in single-cell transcriptomics.
Zheng C, Wang Y, Cheng Y, Wang X, Wei H, King I
Brief Bioinform. 2024; 25(3).
PMID: 38555470
PMC: 10981759.
DOI: 10.1093/bib/bbae112.
Exploration of drug resistance mechanisms in triple negative breast cancer cells using a microfluidic device and patient tissues.
Lim W, Hwang I, Zhang J, Chen Z, Han J, Jeon J
Elife. 2024; 12.
PMID: 38536720
PMC: 10972559.
DOI: 10.7554/eLife.88830.
CRISPRing : A Winding Road with a Bright Future in Basic and Translational Cancer Research.
Gong X, Du J, Peng R, Chen C, Yang Z
Cancers (Basel). 2024; 16(2).
PMID: 38275900
PMC: 10814442.
DOI: 10.3390/cancers16020460.
Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations.
Ding W, Yang P, Zhao X, Wang X, Liu H, Su Q
Respir Res. 2024; 25(1):40.
PMID: 38238740
PMC: 10797755.
DOI: 10.1186/s12931-023-02656-3.
Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies.
Stevens M, Kimmerling R, Olcum S, Vacha M, LaBella R, Minnah A
JCO Precis Oncol. 2024; 8:e2300349.
PMID: 38237098
PMC: 10805426.
DOI: 10.1200/PO.23.00349.
Induces Cancer Cell Death in Breast and Glioblastoma Cancer in 2D/3D Models and Suppresses Breast Cancer Stem Cells.
Azimian Zavareh V, Gharibi S, Rizi M, Nekookar A, Mirhendi H, Rahimmalek M
Cells. 2023; 12(23).
PMID: 38067141
PMC: 10706021.
DOI: 10.3390/cells12232713.
Development of Novel Class of Phenylpyrazolo[3,4-]pyrimidine-Based Analogs with Potent Anticancer Activity and Multitarget Enzyme Inhibition Supported by Docking Studies.
Aljohani A, Zaloa W, Alswah M, Seleem M, Elsebaei M, Bayoumi A
Int J Mol Sci. 2023; 24(19).
PMID: 37834474
PMC: 10573254.
DOI: 10.3390/ijms241915026.
High-content microscopy reveals a morphological signature of bortezomib resistance.
Kelley M, Berman A, Stirling D, Cimini B, Han Y, Singh S
Elife. 2023; 12.
PMID: 37753907
PMC: 10584373.
DOI: 10.7554/eLife.91362.
Profiling of drug resistance in Src kinase at scale uncovers a regulatory network coupling autoinhibition and catalytic domain dynamics.
Chakraborty S, Ahler E, Simon J, Fang L, Potter Z, Sitko K
Cell Chem Biol. 2023; 31(2):207-220.e11.
PMID: 37683649
PMC: 10902203.
DOI: 10.1016/j.chembiol.2023.08.005.
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab.
Marrocco I, Giri S, Simoni-Nieves A, Gupta N, Rudnitsky A, Haga Y
Cell Rep Med. 2023; 4(8):101142.
PMID: 37557179
PMC: 10439256.
DOI: 10.1016/j.xcrm.2023.101142.
Precision Medicine in Bladder Cancer: Present Challenges and Future Directions.
Mohanty S, Lobo A, Mishra S, Cheng L
J Pers Med. 2023; 13(5).
PMID: 37240925
PMC: 10222089.
DOI: 10.3390/jpm13050756.
High-content microscopy reveals a morphological signature of bortezomib resistance.
Kelley M, Berman A, Stirling D, Cimini B, Han Y, Singh S
bioRxiv. 2023; .
PMID: 37205516
PMC: 10187224.
DOI: 10.1101/2023.05.02.539137.
Current Applications of Liquid Biopsy in Gastrointestinal Cancer Disease-From Early Cancer Detection to Individualized Cancer Treatment.
David P, Mittelstadt A, Kouhestani D, Anthuber A, Kahlert C, Sohn K
Cancers (Basel). 2023; 15(7).
PMID: 37046585
PMC: 10093361.
DOI: 10.3390/cancers15071924.
Extrachromosomal circular DNA in cancer drug resistance and its potential clinical implications.
Luo J, Li Y, Zhang T, Xv T, Chen C, Li M
Front Oncol. 2023; 12:1092705.
PMID: 36793345
PMC: 9923117.
DOI: 10.3389/fonc.2022.1092705.
Combination Chemotherapy of Multidrug-resistant Early-stage Colon Cancer: Determining Optimal Dose Schedules by High-performance Computer Simulation.
Cockrell C, Axelrod D
Cancer Res Commun. 2023; 3(1):21-30.
PMID: 36685168
PMC: 9851383.
DOI: 10.1158/2767-9764.crc-22-0271.